biomarkers

Did You Know That Metastatic Prostate Cancer Causes DNA Mutations?

Men with metastatic prostate cancer have higher rates of inherited gene mutations than men with non-metastatic prostate cancer.  Knowing about DNA mutations might help you make better treatment decisions. And you can also tell family members about their risk. Recent studies have shown that metastatic prostate cancer inherited mutations in the DNA-repair genes, such as the BRCA gene, can help guide treatment decisions as well as increase cancer risk in their family members. These mutations are more common in men with metastatic prostate cancer compared with men whose prostate cancer hasn’t spread outside the prostate gland. Men with advanced, metastatic prostate cancer should ask to be [...]

Is Alkaline Phosphatase A Bio-Marker To Predict PSA Decline And Clinical Benefit From Abiraterone Acetate in Bone Metastatic Castration Resistant Prostate Cancer

Again and again I have mentioned the huge need we have for the development of reliable bio-markers. Reliable bio-markers will allow us to know which men will respond positively to a treatment (also those who will not) and when a treatment is still effective (also when it no longer is effective). These biomarkers really don’t exist, so a lot of clinical decision-making is based upon the experience and gut feeling of our doctors. This type of decision-making is not adequate in today’s world of multiple treatment options, especially when many of the treatments can foster resistance to other available treatments. [...]

Standardizing PSA Definition of Biochemical Recurrence after Radical Prostatectomy

There are multiple definitions of biochemical recurrence for prostate cancer treatment post surgery. This causes confusion both within the patient community and the medical community. It would be very helpful if we could standardize a simple measure, PSA as the biomarker for a biochemical recurrence. Standardization post surgery would give us a better way to decide at what point additional treatment would most benefit a man with recurrent prostate cancer. To accomplish this goal researchers reviewed the long-term prostatectomy outcomes to assess the most appropriate prostate specific antigen cut point that predicts future disease progression. The study was large, including [...]

From Active Surveillance to Metastatic Prostate Cancer – Know The Risks As You Decide

Historically, too many men were haphazardly treated for prostate cancer. Happily, the incidents of over treatment have been declining and the general acceptance of Active Surveillance has emerged as the preferred management strategy for men with very low–risk prostate cancer. However, There is still too few high-quality comparative effectiveness studies evaluating the incremental risks associated with or active surveillance. In a prospective study published in the Journal of Urology, researchers reported the risk men face of developing metastatic disease. They evaluated a large, mature, active surveillance cohort. It was reported that, at median follow-up of 6 years, 3.1% of men [...]